Ensign Peak Advisors Inc Purchases New Position in Altimmune, Inc. (NASDAQ:ALT)

Ensign Peak Advisors Inc purchased a new stake in shares of Altimmune, Inc. (NASDAQ:ALT – Get Rating) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 57,300 shares of the company’s stock, valued at approximately $732,000. Ensign Peak Advisors Inc owned about 0.12% of Altimmune as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ALT. JPMorgan Chase & Co. raised its stake in shares of Altimmune by 65.8% in the first quarter. JPMorgan Chase & Co. now owns 307,589 shares of the company’s stock worth $1,873,000 after acquiring an additional 122,021 shares during the last quarter. MetLife Investment Management LLC raised its stake in shares of Altimmune by 65.5% in the first quarter. MetLife Investment Management LLC now owns 21,184 shares of the company’s stock worth $129,000 after acquiring an additional 8,385 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Altimmune in the first quarter worth about $1,108,000. Vanguard Group Inc. raised its stake in shares of Altimmune by 4.8% during the first quarter. Vanguard Group Inc. now owns 1,816,915 shares of the company’s stock worth $11,065,000 after buying an additional 83,160 shares during the last quarter. Finally, XTX Topco Ltd raised its stake in shares of Altimmune by 33.2% during the first quarter. XTX Topco Ltd now owns 19,665 shares of the company’s stock worth $120,000 after buying an additional 4,898 shares during the last quarter. 93.69% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ALT has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Altimmune in a research note on Thursday, March 9th. Evercore ISI boosted their price target on shares of Altimmune from $14.00 to $25.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 18th. Finally, The Goldman Sachs Group initiated coverage on shares of Altimmune in a research note on Thursday, December 1st. They set a “buy” rating and a $20.00 price target for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $29.13.

Insider Activity

In other news, Director Wayne Pisano sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 22nd. The shares were sold at an average price of $15.01, for a total value of $300,200.00. Following the completion of the transaction, the director now owns 8,498 shares in the company, valued at $127,554.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.19% of the company’s stock.

Altimmune Stock Performance

Shares of NASDAQ ALT opened at $10.78 on Tuesday. The stock has a market cap of $531.24 million, a P/E ratio of -6.09 and a beta of 0.11. The firm has a 50 day moving average price of $13.40 and a 200 day moving average price of $13.07. Altimmune, Inc. has a 52-week low of $3.83 and a 52-week high of $23.49.

Altimmune (NASDAQ:ALT – Get Rating) last released its quarterly earnings results on Tuesday, February 28th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.09. The company had revenue of ($0.11) million during the quarter, compared to analysts’ expectations of $0.11 million. Altimmune had a negative net margin of 2,618.74% and a negative return on equity of 44.02%. Analysts predict that Altimmune, Inc. will post -1.94 earnings per share for the current fiscal year.

Altimmune Company Profile

(Get Rating)

Altimmune, Inc is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.